Trial Profile
The Recall-study: Rivastigmine for ECT-induced Cognitive Adverse effects in Late Life Depression: a multicenter, randomized, double-blind, placebo-controlled, crossover trial.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 19 Jul 2018
Price :
$35
*
At a glance
- Drugs Rivastigmine (Primary)
- Indications Delirium
- Focus Therapeutic Use
- Acronyms Recall
- 05 Oct 2016 New trial record